RAB7B: A Target for Anti-Cancer Drugs (G338382)

Target Name: RAB7B

NCBI ID: G338382

RAB7B

RAB7B: A Target for Anti-Cancer Drugs

Ras (Ras-related GTPase) is a gene that encodes a protein involved in cell signaling pathways, specifically the RAS/MAPK pathway. This pathway regulates various cellular processes including cell growth, differentiation, and survival. The RAS/MAPK pathway is a well-established target for numerous drugs, including some anti-cancer drugs, and has been implicated in the development and progression of various diseases, including cancer.

The RAB7B gene is a member of the RAS oncogene family and has been implicated in the regulation of cell signaling pathways. The RAB7B gene encodes a protein that is highly conserved across various species, including humans, and has a similar structure to other RAS proteins. RAB7B is a 21-kDa protein that is expressed in various tissues and cells, including the brain, heart, and pancreas.

The RAB7B gene has four splice variants, with transcript variant 1 being the most abundant and the most well-studied. Transcript variant 1 has a unique exon, which is located at position 194-208, and is the only splice variant that encodes a functional protein. This exon is usually excluded from the final product by alternative splicing, which results in a truncated protein that is missing the N-terminus and a portion of the second exon.

The RAB7B gene has been implicated in various cellular processes, including cell signaling, cell division, and tissue development. The RAB7B protein is involved in the regulation of the RAS/MAPK pathway, which is a well-established target for numerous anti-cancer drugs. The RAB7B protein has been shown to play a role in the regulation of cell proliferation, cell survival, and the development of cancer.

Drugs that target RAB7B have been shown to be effective in treating various diseases, including cancer. For example, the drug gefitinib is a small molecule inhibitor of the RAB7B protein that is currently in use for the treatment of certain types of cancer. Gefitinib has been shown to be effective in treating various types of cancer, including lung cancer and colorectal cancer.

Another drug that targets RAB7B is the drug trazodone, which is a small molecule inhibitor of the RAB7B protein that is currently being studied for the treatment of various types of cancer. Trazodone has been shown to be effective in treating various types of cancer, including lung cancer, breast cancer, and ovarian cancer.

In addition to gefitinib and trazodone, there are other drugs that target RAB7B that are currently in development or have been shown to be effective in preclinical studies. These drugs include the small molecule inhibitor MK-8628, which is being studied for the treatment of various types of cancer, and the monoclonal antibody drug RAB7B-120, which is being developed by the company Roche for the treatment of various types of cancer.

Conclusion

In conclusion, RAB7B is a gene that encodes a protein involved in the RAS/MAPK pathway. This pathway is a well-established target for numerous anti-cancer drugs and has been implicated in the development and progression of various diseases. The RAB7B protein has been shown to play a role in the regulation of cell signaling pathways and has been implicated in the development and progression of cancer. Currently, drugs that target RAB7B are being developed or have been shown to be effective in treating various types of cancer. These drugs include gefitinib, trazodone, and MK-8628, as well as the monoclonal antibody drug RAB7B-120. Further research is needed to fully understand the role of RAB7B in

Protein Name: RAB7B, Member RAS Oncogene Family

Functions: Controls vesicular trafficking from endosomes to the trans-Golgi network (TGN). Acts as a negative regulator of TLR9 signaling and can suppress TLR9-triggered TNFA, IL6, and IFNB production in macrophages by promoting TLR9 lysosomal degradation. Also negatively regulates TLR4 signaling in macrophages by promoting lysosomal degradation of TLR4. Promotes megakaryocytic differentiation by increasing NF-kappa-B-dependent IL6 production and subsequently enhancing the association of STAT3 with GATA1. Not involved in the regulation of the EGF- and EGFR degradation pathway

The "RAB7B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB7B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets